

DermaSensor Crowned by SXSW as the 2024 Innovation Winner for Health and Biotech

DermaSensor Inc. proudly announces its victory in the SXSW Innovation Award for the Health and Biotech category.

MIAMI, FLORIDA, UNITED STATES, March 13, 2024 /EINPresswire.com/ -- DermaSensor Inc., a leading provider of innovative solutions for [skin cancer detection](#), proudly announces its victory in the SXSW Innovation Award for the Health and Biotech category. This esteemed award recognizes the most groundbreaking advancements in the connected world, highlighting exceptional achievements in technology across various sectors.

The Health and Biotech category, one of the most anticipated segments of the awards, spotlights revolutionary projects dedicated to enhancing wellness and medicine. DermaSensor's win underscores its commitment to improving skin cancer detection and patient care through cutting-edge technology.

Larry Anderson, Jr., Chief Commercial Officer of DermaSensor, expressed his gratitude, stating, "Presenting on behalf of the DermaSensor Team at the SXSW Innovation Awards, and receiving this recognition among some of the most innovative Health and Biotech companies, was truly an honor. This recognition is well aligned with our mission to empower clinicians with intelligent,



SXSW 2024 Winner Logo

objective solutions, leveraging data-driven breakthrough technologies to enhance skin cancer detection and patient care."

DermaSensor's innovative approach combines artificial intelligence and data analytics to provide clinicians with reliable, objective real-time skin cancer assessment by harnessing the power of optical spectroscopy technology. DermaSensor aims to make significant strides in improving physicians' detection of skin cancer and the efficiency of skin cancer related referrals. The recognition at the Health and Biotech 2024 SXSW Innovation Awards reaffirms DermaSensor's position as a leader in this area of healthcare technology.

About DermaSensor

DermaSensor Inc. is a health technology company designing non-invasive tools to better equip primary care physicians for skin cancer detection. The DermaSensor device is an affordable, handheld tool that uses spectroscopy and algorithms to evaluate skin lesions for potential cancer in a matter of seconds. DermaSensor device is currently FDA-Cleared, CE-Marked, and is available for sale in the U.S.

Larry Anderson
DermaSensor, Inc.
+1 213-219-5862

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/695395363>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.